Document Detail

Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice.
MedLine Citation:
PMID:  11016643     Owner:  NLM     Status:  MEDLINE    
Doxorubicinol (dxol) is the major metabolite formed in the hearts of cancer patients being treated with the widely used chemotherapeutic agent, doxorubicin (dox). The well-documented cardiomyopathy associated with dox treatment has been studied in vitro and ex vivo providing evidence that the C-13 hydroxy metabolite, dxol, might play a key role in the development of dox-induced cardiotoxicity. In this report, we have developed transgenic mice with heart-specific expression of human carbonyl reductase (HCBR), an enzyme that metabolizes dox to dxol. Dox was rapidly converted to dxol in the hearts of the transgenic expressers, which led to advanced development of both acute and chronic cardiotoxicity. Acute cardiotoxicity was evident by a 60% increase in serum creatine kinase activity and a 5-fold increase in cardiac damage measured by electron microscopy. Myofibril degeneration was the major damage observed in acute dox toxicity. Electrocardiograph telemetry, survival data, and electron microscopy were monitored during chronic dox-induced cardiotoxicity. HCBR expressers developed cardiotoxicity 6-7 weeks before the nonexpressers. The HCBR expressers survived for 5 weeks compared with 12 weeks for the controls. Electrocardiograph profiles and necropsies showed the cause of death to be the development of cardiomyopathies leading to congestive heart failure. Levels of dxol were four times higher in the HCBR expresser hearts than in the nonexpressers. Electron microscopy data showed swelling and major structural damage of the mitochondria in the HCBR expressers. These data demonstrate that the C-13 hydroxy metabolite of dox advances the development of dox-induced cardiotoxicity in an in vivo system and suggest that heart carbonyl reductase activity may contribute to dox-induced cardiotoxicity in humans.
G L Forrest; B Gonzalez; W Tseng; X Li; J Mann
Related Documents :
15475963 - Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion pert...
1509783 - Cheyne-stokes respiration in congestive heart failure.
8291393 - Aana journal course: update for nurse anesthetists--anesthetic techniques for patients ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  Cancer research     Volume:  60     ISSN:  0008-5472     ISO Abbreviation:  Cancer Res.     Publication Date:  2000 Sep 
Date Detail:
Created Date:  2000-10-13     Completed Date:  2000-10-13     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  2984705R     Medline TA:  Cancer Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  5158-64     Citation Subset:  IM    
Department of Biology, Beckman Research Institute at the City of Hope, Duarte, CA 91010, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alcohol Oxidoreductases / biosynthesis*,  genetics,  metabolism
Antibiotics, Antineoplastic / metabolism,  toxicity*
Creatine Kinase / blood
Disease Models, Animal
Doxorubicin / analogs & derivatives*,  metabolism,  toxicity*
Electrocardiography, Ambulatory
Heart Diseases / chemically induced*,  enzymology
Mice, Inbred Strains
Mice, Transgenic
Microscopy, Electron
Mitochondria, Heart / drug effects
Myocardium / enzymology*
Organ Specificity
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 141434-67-5/adriamycinol; 23214-92-8/Doxorubicin; EC 1.1.-/Alcohol Oxidoreductases; EC Kinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in hu...
Next Document:  Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prost...